JP2008519818A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008519818A5 JP2008519818A5 JP2007540742A JP2007540742A JP2008519818A5 JP 2008519818 A5 JP2008519818 A5 JP 2008519818A5 JP 2007540742 A JP2007540742 A JP 2007540742A JP 2007540742 A JP2007540742 A JP 2007540742A JP 2008519818 A5 JP2008519818 A5 JP 2008519818A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- pharmaceutically acceptable
- disease
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 241000701022 Cytomegalovirus Species 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- -1 —CF 3 Chemical group 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims 1
- LCFZZQANSOSPPC-UHFFFAOYSA-N 2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-5-(2-phenylethyl)-[1,3]oxazolo[4,5-b]pyridine Chemical compound C=1C=C2OC(N3C4CCN(CC4)CC3)=NC2=NC=1CCC1=CC=CC=C1 LCFZZQANSOSPPC-UHFFFAOYSA-N 0.000 claims 1
- YABLRALLVGHPFP-UHFFFAOYSA-N 2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-5-ethyl-[1,3]oxazolo[4,5-b]pyridine Chemical compound N=1C2=NC(CC)=CC=C2OC=1N1CCN2CCC1CC2 YABLRALLVGHPFP-UHFFFAOYSA-N 0.000 claims 1
- GQEKICZTZMCCOT-UHFFFAOYSA-N 2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-5-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridine Chemical compound C1COCCN1C1=CC=C(OC(=N2)N3C4CCN(CC4)CC3)C2=N1 GQEKICZTZMCCOT-UHFFFAOYSA-N 0.000 claims 1
- FSPOUWAFZGKHDS-UHFFFAOYSA-N 2-(1,4-diazabicyclo[3.2.2]nonan-4-yl)-5-phenyl-[1,3]oxazolo[4,5-b]pyridine Chemical compound C1CN(CC2)CCC1N2C(OC1=CC=2)=NC1=NC=2C1=CC=CC=C1 FSPOUWAFZGKHDS-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010063094 Cerebral malaria Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000010191 Osteitis Deformans Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000027868 Paget disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010036631 Presenile dementia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000000164 antipsychotic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000019664 bone resorption disease Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 231100000870 cognitive problem Toxicity 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022000 influenza Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 210000004558 lewy body Anatomy 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 208000027202 mammary Paget disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000005586 smoking cessation Effects 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000003519 ventilatory effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60896404P | 2004-11-15 | 2004-11-15 | |
| PCT/IB2005/003364 WO2006051394A1 (en) | 2004-11-15 | 2005-11-03 | Azabenzoxazoles for the treatment of cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008519818A JP2008519818A (ja) | 2008-06-12 |
| JP2008519818A5 true JP2008519818A5 (enExample) | 2008-12-25 |
Family
ID=35636743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007540742A Abandoned JP2008519818A (ja) | 2004-11-15 | 2005-11-03 | Ｃｎｓ障害の治療のためのアザベンゾオキサゾール |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20060173179A1 (enExample) |
| EP (1) | EP1814888A1 (enExample) |
| JP (1) | JP2008519818A (enExample) |
| AR (1) | AR051955A1 (enExample) |
| CA (1) | CA2587461A1 (enExample) |
| GT (1) | GT200500332A (enExample) |
| NL (1) | NL1030418C2 (enExample) |
| PE (1) | PE20061133A1 (enExample) |
| TW (1) | TW200631956A (enExample) |
| UY (1) | UY29212A1 (enExample) |
| WO (1) | WO2006051394A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2774925B1 (en) | 2005-11-08 | 2016-12-28 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of ATP-binding cassette transporters |
| WO2007083954A1 (en) * | 2006-01-23 | 2007-07-26 | Lg Electronics Inc. | Method for scheduling device management and terminal thereof |
| WO2008141119A2 (en) | 2007-05-09 | 2008-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
| HUE031913T2 (en) | 2007-12-07 | 2017-08-28 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid |
| PL2231606T3 (pl) * | 2007-12-07 | 2013-07-31 | Vertex Pharma | Sposoby wytwarzania kwasów cykloalkilokarboksyamidopirydynobenzoesowych |
| JP5523352B2 (ja) | 2008-02-28 | 2014-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｆｔｒ修飾因子としてのへテロアリール誘導体 |
| JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
| RS62767B1 (sr) | 2010-04-07 | 2022-01-31 | Vertex Pharma | Farmaceutski sastavi 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il) ciklopropankarboksamido)-3-metilpiriodin-2-il)benzojeve kiseline i njihova primena |
| US20140171448A1 (en) * | 2011-01-27 | 2014-06-19 | Novartis Ag | Use of nicotinic acetylcholine receptor alpha 7 activators |
| MX355183B (es) | 2012-01-25 | 2018-04-09 | Vertex Pharma | Formulaciones de acido 3- (6- (1- (2.2- difluorobenzo [d] [1,3] dioxol-5-il) ciclopropancarboxamido) -3- metilpiridin-2-il) benzoico. |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| HRP20210516T2 (hr) | 2013-11-12 | 2021-10-01 | Vertex Pharmaceuticals Incorporated | Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr |
| KR102576006B1 (ko) | 2014-11-18 | 2023-09-06 | 버텍스 파마슈티칼스 인코포레이티드 | 고처리량 시험 고성능 액체 크로마토그래피의 수행 방법 |
| CN107188900B (zh) * | 2017-05-27 | 2019-09-06 | 北京师范大学 | α7烟碱型乙酰胆碱受体的配体化合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020086871A1 (en) * | 2000-12-29 | 2002-07-04 | O'neill Brian Thomas | Pharmaceutical composition for the treatment of CNS and other disorders |
| FR2832714B1 (fr) * | 2001-11-23 | 2004-07-16 | Sanofi Synthelabo | Derives de 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique |
| CA2549638A1 (en) * | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
-
2005
- 2005-11-03 CA CA002587461A patent/CA2587461A1/en not_active Abandoned
- 2005-11-03 WO PCT/IB2005/003364 patent/WO2006051394A1/en not_active Ceased
- 2005-11-03 JP JP2007540742A patent/JP2008519818A/ja not_active Abandoned
- 2005-11-03 EP EP05805178A patent/EP1814888A1/en not_active Withdrawn
- 2005-11-11 PE PE2005001321A patent/PE20061133A1/es not_active Application Discontinuation
- 2005-11-11 AR ARP050104739A patent/AR051955A1/es unknown
- 2005-11-14 NL NL1030418A patent/NL1030418C2/nl not_active IP Right Cessation
- 2005-11-14 US US11/273,657 patent/US20060173179A1/en not_active Abandoned
- 2005-11-14 UY UY29212A patent/UY29212A1/es not_active Application Discontinuation
- 2005-11-14 TW TW094139977A patent/TW200631956A/zh unknown
- 2005-11-15 GT GT200500332A patent/GT200500332A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010540562A5 (enExample) | ||
| US10604504B2 (en) | Indole carboxamide compounds | |
| JP6062999B2 (ja) | 治療用化合物、及び関連する使用の方法 | |
| JP6121658B2 (ja) | 治療用化合物、及び関連する使用の方法 | |
| JP6306053B2 (ja) | ２，３−ジヒドロイミダゾール［１，２−ｃ］ピリミジン−５（１Ｈ）−オンに基づくリポタンパク質関連ホスホリパーゼＡ２（Ｌｐ−ＰＬＡ２）阻害剤 | |
| JP2008513516A5 (enExample) | ||
| JP2019522007A5 (enExample) | ||
| JP2010510237A5 (enExample) | ||
| MX2013015204A (es) | Quinazolinas como compuestos terapeuticos, y metodos de uso relacionados. | |
| KR20180003612A (ko) | 바이러스 감염의 치료 및 예방을 위한 신규한 설폰이미도일푸린온 화합물 및 유도체 | |
| JP2011529468A5 (enExample) | ||
| JP2008511574A5 (enExample) | ||
| EP1412028A1 (en) | Tetrahydroindolone and purine derivatives linked to arylpiperazines | |
| JP2008519818A (ja) | Ｃｎｓ障害の治療のためのアザベンゾオキサゾール | |
| RU2006103790A (ru) | Производные такрина в качестве ингибиторов ацетилхолинэстеразы | |
| WO2004094379A3 (en) | 3-phenyl-4- (pyrimidin-2-yl) -6- (piperidin-4-yl) derivatives and related compounds as tnf-alpha and il-1 inhibitors for the treatment of inflammations | |
| JP2008509104A5 (enExample) | ||
| Ghorbani-Vaghei et al. | Effective DABCO-catalyzed synthesis of new tetrazolo [1, 5-a] pyrimidine analogs | |
| JP4403305B2 (ja) | １，３−ベンゾチアジノン誘導体および用途 | |
| ATE393157T1 (de) | Substituierte heterocyclische verbindungen und anwendungsverfahren | |
| JP2007515480A5 (enExample) | ||
| HK1235064A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| TW201341371A (zh) | ４，４－二取代－１，４－二氫嘧啶類及其作為用於治療ｂ型肝炎的藥劑之用途 |